Moderna Co-Founder Robert Langer to Step Down from Vaccine Maker's Board
According to a new report from Reuters, Dr. Robert Runge, a high-profile scientist and co-founder of biotech giant Moderna, has officially announced that he is stepping down from the company's board of directors. This news has caused widespread concern and discussion in the industry.
Dr. Lange is not only one of the key founders of Moderna, but also the soul behind it. He has served as a member of the Board of Directors of the Company since its inception, providing solid technical support and strategic guidance for the company's development. However, Dr. Langer decided to step down from the board this time, explaining that he was doing so in order to focus more on his faculty work at MIT and his own research and development in other innovative projects in the field of biotechnology.
Moderna was quick to respond to the decision after the news was released. Although Dr. Langer is stepping down, he will continue to serve as an advisor at various levels of the company and will continue to provide valuable advice and support to the company's growth. Dr. Langer has made an indelible contribution to Moderna's rapid growth over the years, and the company's top executives express their deep regret at his departure and wish him well for his future career.
Dr. Lange's exit has been deeply discussed and analyzed by analysts. They believe that in the short term, Dr. Langer's departure may have some impact on Moderna, after all, he is one of the soul of the company. However, in the long run, this decision will not have a significant impact on the company's overall strategy and business. Moderna has built a strong research and development team and has accumulated extensive experience in the field of biotechnology. The company is actively laying out new disease areas to maintain a strong research and development momentum.
In addition, analysts noted that Dr. Langer's departure from the board would not break his close ties to Moderna. He will continue to participate in the company's decision-making and research and development as a consultant and contribute to the company's development. This partnership model not only helps to maintain Moderna's leading position in biotechnology, but also helps to drive innovation and development across the industry.
Although Dr. Lange's departure brought a certain shock to Moderna, it also injected new vitality and momentum into the future development of the company. We have every reason to believe that with the joint efforts of all employees, Moderna will continue to achieve more brilliant achievements in the field of biotechnology.
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Middle East Capital Moves In: SABIC Plans RMB 33 Billion Stake in Rongsheng Petrochemical
-
Argentina to Build Latin America’s Largest Urea Plant Under €1.3 Billion Contract
-
Multiple Chemical Industry Leaders Post Strong H1 Earnings Growth as Sector Profitability Revives
-
Türkiye Advances $3 Billion Petrochemical Cluster Targeting 17% of Domestic Polypropylene Demand
-
Dow Swings from an $801 Million Loss to an $802 Million Profit as Hormuz Disruption Lifts Polyethylene Prices
-
BASF-Evonik Takeover Faces Political Resistance as German State Defends Jobs and Independence
-
BASF Sues Apple Over Face Authentication Patents Used in Dozens of iPhones and iPads
-
BASF Raises Acid Chloride and Chloroformate Capacity by 30% at Ludwigshafen
-
Sinopec Oilfield Service Chairman Steps Down, Sinopec Shanghai Sales Branch Deputy GM Investigated on Consecutive Days
-
Ineos Rescues UK's Last Dichloroethane Plant
Recommend Reading
-
Dow Europe Raises Polyurethane Prices in EMEA and India
-
BASF Moves to Sell 4,400 Employee Homes—Union Fury Reveals the Survival Math of a Chemical Giant
-
The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time
-
China Activates Blocking Rules in Response to U.S. Sanctions on Petrochemical Firms
-
BASF’s 2025 Report Card—“The Profit Evaporation Act”: Behind the €6.6 Billion EBITDA Lies a Deliberate Strategic Retreat
-
Business Society’s August 26, 2026 View on Isooctanol Market Trends: A Phase of Adjustment
-
On March 9, the Isopropyl Alcohol Market in China Experienced a Significant Price Increase
-
Business Society’s Market Outlook for Lithium Carbonate on September 2, 2026: Volatile
-
This week, the price of China's 180CST fuel oil has fallen from its high position
-
Business Society’s August 26, 2026 Phthalic Anhydride Market Outlook: Clearly Upward Trend